profit from every $100 of sales.
$0$100
Aytu BioPharma
$1.79-2.19% today
-11.8% in 1 year
1-year low $1.791-year high $2.90
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Aytu BioPharma sold, what it kept, and what it did with the cash.
Sales went from $96.7 million in 2022 to $66.4 million in 2025, with -$13.6 million of profit last year.
SalesProfit
Aytu BioPharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Aytu BioPharma | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Aytu BioPharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 97 | 107 | 65 | 66 | |
| 52 | 67 | 49 | 46 | |
| -36 | -12 | 1 | 3 | |
| -26 | -3 | 1 | -5 | |
| -109 | -17 | -16 | -14 | |
| -75.00 | -5.11 | -2.86 | -2.16 | |
| 54.1% | 62.0% | 75.3% | 69.0% | |
| -37.3% | -11.5% | 0.9% | 3.8% | |
| -112.5% | -15.9% | -24.3% | -20.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 138 | 136 | 118 | 124 |
| Cash | 19 | 23 | 20 | 31 |
| Total debt | 18 | 16 | 15 | 22 |
| Total liabilities | 93 | 97 | 90 | 105 |
| 44 | 39 | 28 | 19 | |
| 1 | 3 | 6 | 6 | |
| -45.6% | -17.1% | -9.8% | -19.5% | |
| -245.5% | -43.3% | -57.2% | -71.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -5 | -1 | -2 | |
| – | – | 0 | 3 | |
| -29 | -5 | -2 | -5 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 6 | 2 | 1 |
Valuation
- –
- –
- –
- 1.8×
- 0.3×
- –
- –
- -26.6%
- -69.7%
- 0.0%
Profitability
- 69.0%
- 3.8%
- -20.4%
- -27.5%
- -12.8%
- -60.3%
- -107.2%
- -20.0%
- -15.4%
- 0.6%
Growth
- −11.8%
- –
- −200.8%
- –
- +65.4%
Financial health
- -2.0×
- 1.62
- 18.9%
- -3.2×
- 1.16
- 1.03
- 0.51
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 26%of 948
Bottom 37%of 871
Bottom 7%of 868
Bottom 2%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.53 | -0.31 | −71.0% |
| Feb 3, 2026 | -1.05 | -0.26 | −303.8% |
| Nov 13, 2025 | -0.08 | -0.06 | −33.3% |
| Sep 23, 2025 | -0.26 | -0.02 | −1,200.0% |
| May 14, 2025 | 0.20 | -0.17 | +217.6% |
| Feb 12, 2025 | -0.28 | -0.28 | +0.0% |
| Nov 13, 2024 | -0.20 | -0.34 | +41.2% |
| Sep 26, 2024 | -0.82 | -0.45 | −82.2% |
News
Aytu outlines $49M-$54M FY27 operating expense plan as it targets 66%-67% gross margin in Q4 FY27Seeking Alpha · Sep 22, 2026The newest story we have is from Sep 22, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
31No pass
Philip Fisher
36No pass
Peter Lynch
13No pass
Joel Greenblatt
0No pass
Charlie Munger
22No pass
Terry Smith
21No pass
Questions about Aytu BioPharma
Is Aytu BioPharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aytu BioPharma AI analysis
What does Aytu BioPharma do?
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. It is in Drug Manufacturers - Specialty & Generic.
Does Aytu BioPharma pay a dividend?
No. Aytu BioPharma does not pay a dividend at the moment.
Is Aytu BioPharma stock halal?
No. Aytu BioPharma does not pass our halal screen: its debt is 112% of its market value, at or above the 33% limit. How we check
How has Aytu BioPharma stock done over the past year?
Down 11.8% over the past twelve months, to $1.79. It traded between $1.79 and $2.90 and is 38.3% below its high.
Who are Aytu BioPharma's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Aytu BioPharma's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.